The FDA’s Expedited Investigational New Drug (IND) Pilot pairs drug sponsors with research institutions to reduce startup delays for early human studies.
RT’s Three Key Takeaways:
- Accelerated Study Timelines: The FDA announced the final design of its Expedited Investigational New Drug (IND) Pilot to shorten the timeline between drug discovery and the launch of first-in-human clinical trials.
- Rolling Component Review: The program enables rolling reviews of IND application components during the pre-IND phase by partnering commercial sponsors with qualified research institutions to address regulatory issues before official submission.
- Application Window Open: Sponsor and research institution pairs can apply to participate in the initial pilot cohort through October 30, 2026, with the agency planning to select eight to 10 pairs.
The USFDA announced the final design of its Expedited Investigational New Drug (IND) Pilot, an initiative intended to reduce clinical trial startup delays and speed the transition from laboratory discovery to first-in-human trials, according to the agency.
Under current timelines, initial human clinical trials can require up to two years to begin in the US, whereas similar studies proceed more rapidly in countries such as China and Australia, the FDA stated. Operating as part of the US Department of Health and Human Services’ Operation TrialBlazer and broader federal healthcare modernization initiatives, the pilot seeks to address early development bottlenecks by pairing pharmaceutical developers with qualified research institutions (QRIs) possessing specialized scientific expertise.
“The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed,” said Kyle Diamantas, JD, acting FDA commissioner. “Under the Trump Administration, boosting domestic innovation and ensuring American patients have first access to groundbreaking treatments is a top priority. The FDA will continue implementing Operation TrialBlazer to modernize regulatory processes to keep our country ahead of global competitors without compromising patient safety.”
Rolling Reviews and Early Institutional Coordination
First-in-human trials serve a critical role in establishing dosing parameters, drug absorption, and safety profiles necessary for regulatory evaluation, the FDA noted. Through the pilot structure, participating QRIs will assist drug sponsors in assembling IND filings, permitting FDA reviewers to evaluate individual submission elements on a rolling basis during the pre-IND phase rather than waiting for an entire dossier.
Agency officials reported that this real-time identification and resolution of potential application deficiencies is intended to lower the likelihood of clinical holds during the standard 30-day IND review window. Additionally, the framework encourages early alignment of parallel startup tasks, including institutional review board assessments and clinical site activations, to minimize administrative downtime between filing preparation and participant enrollment.
“The pilot hopes to utilize the American innovation ecosystem to accelerate the time to first-in-human clinical trials,” said Karim Mikhail, B Pharm, MS, director of the Center for Biologics Evaluation and Research (CBER). “The FDA is doing our part to ensure American patients continue to receive access to therapies first, while keeping scientific innovation and investment in America.”
Regulatory Oversight and Cohort Participation
The FDA emphasized that it retains complete regulatory oversight throughout the program, including final determinations regarding study clearance and the implementation of clinical holds. Data gathered during the initiative will help evaluate future policy concepts, such as an accreditation pathway for research institutions demonstrating strong scientific and regulatory capabilities, the release indicated.
“The FDA greatly appreciates the public feedback we received on the proposed pilot, and we have incorporated that feedback into the final pilot design,” said Michael Davis, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research (CDER). “The FDA is committed to ensuring the United States remains the global standard for pharmaceutical innovation and regulatory rigor for the benefit of American patients and innovators.”
Applications must be submitted jointly by commercial drug sponsors and prospective QRIs through October 30, 2026, according to the agency. FDA scientific staff will evaluate the submissions, with eight to 10 sponsor-QRI pairs anticipated for selection in the initial pilot cohort.
